The cellular and molecular mechanisms mediating the protective effects of sodium–glucose linked transporter 2 inhibitors against metabolic dysfunction‐associated fatty liver disease.

Ao, Na; Du, Jian; Jin, Shi; Suo, Linna; Yang, Jing

Metabolic dysfunction‐associated fatty liver disease (MAFLD), formerly known as nonalcoholic fatty liver disease (NAFLD), is a common, highly heterogeneous condition that affects about a quarter of the world's population, with no approved drug therapy. Current evidence from preclinical research and a number of small clinical trials indicates that SGLT2 inhibitors could also be effective for MAFLD. MAFLD is associated with a higher risk of chronic liver disease and multiple extrahepatic events, especially cardiovascular disease (CVD) and chronic kidney disease (CKD). MAFLD is considered a more appropriate terminology than NAFLD because it captures the complex bidirectional interplay between fatty liver and metabolic dysfunctions associated with disease progression, such as obesity and type 2 diabetes mellitus (T2DM). SGLT2 inhibitors are antidiabetic drugs that block glucose reabsorption in the kidney proximal tubule. In this article, we reviewed current clinical evidence supporting the potential use of SGLT2 inhibitors as a drug therapy for MAFLD and discussed the possible cellular and molecular mechanisms involved. We also reviewed the clinical benefits of SGLT2 inhibitors against MAFLD‐related comorbidities, especially CVD, CKD and cardiovascular–kidney–metabolic syndrome (CKM). The broad beneficial effects of SGLT2 inhibitors support their use, likely in combination with other drugs, as a therapy for MAFLD.

NON-alcoholic fatty liver disease; FATTY liver; PROXIMAL kidney tubules; TYPE 2 diabetes; SODIUM-glucose cotransporter 2 inhibitors

Diabetes, Obesity & Metabolism, 2025, Vol 27, Issue 2, p457

1462-8902

Academic Journal

10.1111/dom.16043